The earnings call reflected a positive overall sentiment driven by significant revenue growth, strategic expansions, and successful financing, despite some challenges with higher discounts and increased net loss.

Company Guidance

During the third quarter 2024 earnings call for scPharmaceuticals (SCPH), key guidance included several financial and operational metrics. The company reported net revenue of $10 million, marking a 24% increase from the previous quarter, despite some challenges in the latter half of Q3 due to coverage gap rebates impacting their gross-to-net (GTN) discount, which was 15.7%, slightly above the anticipated 10% to 15% range. The GTN is expected to remain within this range for the rest of 2024, but an increase up to 35% is anticipated by the end of 2025 due to the Medicare Part D redesign. The company also highlighted the expansion of FUROSCIX's indication to include Class IV heart failure patients and the acceptance of a supplemental NDA for its use in chronic kidney disease (CKD), with a PDUFA date set for March 6, 2025. Additionally, scPharmaceuticals completed a transformative financing round, adding $75 million to its balance sheet, positioning the company towards expected profitability.

Revenue Growth

Net revenue for Q3 2024 was $10 million, representing an approximately 24% increase from Q2 2024.

FUROSCIX Expansion and sNDA Acceptance

Acceptance of sNDA filing by the FDA to expand FUROSCIX indication to include treatment of edema in CKD patients.

Increased Prescriber Base

Approximately 3,100 unique healthcare providers have prescribed FUROSCIX, a 13% increase compared to Q2 2024.

Positive Autoinjector Study

Announced positive top-line results from a PK/PD bridging study for the low-volume Autoinjector.

Transformative Financing

Completed financing that resulted in a net addition of roughly $75 million, bolstering the cash runway through expected profitability.

---

scPharmaceuticals (SCPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SCPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 21, 2019	2018 (Q4)	- / -0.27	-0.8	66.25% (+0.53)	―	―
May 08, 2019	2019 (Q1)	- / -0.47	-0.47	0.00% (0.00)	―	―
Aug 07, 2019	2019 (Q2)	- / -0.39	-0.53	26.42% (+0.14)	―	―
Nov 12, 2019	2019 (Q3)	- / -0.33	-0.31	-6.45% (-0.02)	―	―
Mar 24, 2020	2019 (Q4)	- / -0.58	-0.27	-114.81% (-0.31)	―	―
May 12, 2020	2020 (Q1)	- / -0.35	-0.47	25.53% (+0.12)	―	―
Aug 13, 2020	2020 (Q2)	- / -0.36	-0.39	7.69% (+0.03)	―	―
Nov 16, 2020	2020 (Q3)	- / -0.33	-0.33	0.00% (0.00)	―	―
Mar 24, 2021	2020 (Q4)	- / -0.28	-0.58	51.72% (+0.30)	―	―
May 12, 2021	2021 (Q1)	-0.30 / -0.26	-0.35	25.71% (+0.09)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

SCPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 13, 2024	$3.91	$3.36	-14.07%
Aug 14, 2024	$4.79	$5.06	+5.64%
May 14, 2024	$4.50	$4.57	+1.56%
Mar 13, 2024	$5.44	$5.30	-2.57%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---